Abbott Laboratories (ABT): Operating Cash Flow
$9.57B
Year ended 2025-12-31
$9.46B
Trailing 12 months to 2026-03-31
-0.1%
3-year compound annual growth
+3.9%
5-year compound annual growth
+12.4%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.57B | +11.8% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $8.56B | +17.9% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $7.26B | -24.2% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $9.58B | -9.0% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $10.53B | +33.3% | 2024-02-16, From 2021-01-01 |
| 2020-12-31 | $7.90B | +28.8% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $6.14B | -2.6% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $6.30B | +13.1% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $5.57B | +73.9% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $3.20B | +8.0% | 2019-02-22, From 2016-01-01 |
| 2015-12-31 | $2.97B | -19.3% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $3.67B | +10.6% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $3.32B | -64.3% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $9.31B | +3.8% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $8.97B | n/a | 2014-02-21, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $19.03B | +1.2% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
Compare ABT, BMY, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗